Clinical and Genetic Characteristics of Non-Insulin-Requiring Glutamic Acid Decarboxylase (GAD) Autoantibody-Positive Diabetes: A Nationwide Survey in Japan.
AIMS:Glutamic acid decarboxylase autoantibodies (GADAb) differentiate slowly progressive insulin-dependent (type 1) diabetes mellitus (SPIDDM) from phenotypic type 2 diabetes, but many GADAb-positive patients with diabetes do not progress to insulin-requiring diabetes. To characterize GADAb-positive...
Main Authors: | , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4866691?pdf=render |
id |
doaj-a964ce02ffde48f1ab97805501b3aba1 |
---|---|
record_format |
Article |
spelling |
doaj-a964ce02ffde48f1ab97805501b3aba12020-11-24T20:50:51ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01115e015564310.1371/journal.pone.0155643Clinical and Genetic Characteristics of Non-Insulin-Requiring Glutamic Acid Decarboxylase (GAD) Autoantibody-Positive Diabetes: A Nationwide Survey in Japan.Junichi YasuiEiji KawasakiShoichiro TanakaTakuya AwataHiroshi IkegamiAkihisa ImagawaYasuko UchigataHaruhiko OsawaHiroshi KajioYumiko KawabataAkira ShimadaKazuma TakahashiKazuki YasudaHisafumi YasudaToshiaki HanafusaTetsuro KobayashiJapan Diabetes Society Committee on Type 1 Diabetes Mellitus ResearchAIMS:Glutamic acid decarboxylase autoantibodies (GADAb) differentiate slowly progressive insulin-dependent (type 1) diabetes mellitus (SPIDDM) from phenotypic type 2 diabetes, but many GADAb-positive patients with diabetes do not progress to insulin-requiring diabetes. To characterize GADAb-positive patients with adult-onset diabetes who do not require insulin therapy for >5 years (NIR-SPIDDM), we conducted a nationwide cross-sectional survey in Japan. METHODS:We collected 82 GADAb-positive patients who did not require insulin therapy for >5 years (NIR-SPIDDM) and compared them with 63 patients with insulin-requiring SPIDDM (IR-SPIDDM). Clinical and biochemical characteristics, HLA-DRB1-DQB1 haplotypes, and predictive markers for progression to insulin therapy were investigated. RESULTS:Compared with the IR-SPIDDM group, the NIR-SPIDDM patients showed later diabetes onset, higher body mass index, longer duration before diagnosis, and less frequent hyperglycemic symptoms at onset. In addition, C-peptide, LDL-cholesterol, and TG were significantly higher in the NIR-SPIDDM compared to IR-SPIDDM patients. The NIR-SPIDDM group had lower frequency of susceptible HLA-DRB1*04:05-DQB1*04:01 and a higher frequency of resistant HLA-DRB1*15:01-DQB1*06:02 haplotype compared to IR-SPIDDM. A multivariable analysis showed that age at diabetes onset (OR = 0.82), duration before diagnosis of GADAb-positive diabetes (OR = 0.82), higher GADAb level (≥10.0 U/ml) (OR = 20.41), and fasting C-peptide at diagnosis (OR = 0.07) were independent predictive markers for progression to insulin-requiring diabetes. An ROC curve analysis showed that the optimal cut-off points for discriminating two groups was the GADAb level of 13.6 U/ml, age of diabetes onset of 47 years, duration before diagnosis of 5 years, and fasting C-peptide of 0.65 ng/ml. CONCLUSIONS:Clinical, biochemical and genetic characteristics of patients with NIR-SPIDDM are different from those of IR-SPIDDM patients. Age of diabetes onset, duration before GADAb-positivity, GADAb level, and fasting C-peptide at diagnosis must be carefully considered in planning prevention trials for SPIDDM.http://europepmc.org/articles/PMC4866691?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Junichi Yasui Eiji Kawasaki Shoichiro Tanaka Takuya Awata Hiroshi Ikegami Akihisa Imagawa Yasuko Uchigata Haruhiko Osawa Hiroshi Kajio Yumiko Kawabata Akira Shimada Kazuma Takahashi Kazuki Yasuda Hisafumi Yasuda Toshiaki Hanafusa Tetsuro Kobayashi Japan Diabetes Society Committee on Type 1 Diabetes Mellitus Research |
spellingShingle |
Junichi Yasui Eiji Kawasaki Shoichiro Tanaka Takuya Awata Hiroshi Ikegami Akihisa Imagawa Yasuko Uchigata Haruhiko Osawa Hiroshi Kajio Yumiko Kawabata Akira Shimada Kazuma Takahashi Kazuki Yasuda Hisafumi Yasuda Toshiaki Hanafusa Tetsuro Kobayashi Japan Diabetes Society Committee on Type 1 Diabetes Mellitus Research Clinical and Genetic Characteristics of Non-Insulin-Requiring Glutamic Acid Decarboxylase (GAD) Autoantibody-Positive Diabetes: A Nationwide Survey in Japan. PLoS ONE |
author_facet |
Junichi Yasui Eiji Kawasaki Shoichiro Tanaka Takuya Awata Hiroshi Ikegami Akihisa Imagawa Yasuko Uchigata Haruhiko Osawa Hiroshi Kajio Yumiko Kawabata Akira Shimada Kazuma Takahashi Kazuki Yasuda Hisafumi Yasuda Toshiaki Hanafusa Tetsuro Kobayashi Japan Diabetes Society Committee on Type 1 Diabetes Mellitus Research |
author_sort |
Junichi Yasui |
title |
Clinical and Genetic Characteristics of Non-Insulin-Requiring Glutamic Acid Decarboxylase (GAD) Autoantibody-Positive Diabetes: A Nationwide Survey in Japan. |
title_short |
Clinical and Genetic Characteristics of Non-Insulin-Requiring Glutamic Acid Decarboxylase (GAD) Autoantibody-Positive Diabetes: A Nationwide Survey in Japan. |
title_full |
Clinical and Genetic Characteristics of Non-Insulin-Requiring Glutamic Acid Decarboxylase (GAD) Autoantibody-Positive Diabetes: A Nationwide Survey in Japan. |
title_fullStr |
Clinical and Genetic Characteristics of Non-Insulin-Requiring Glutamic Acid Decarboxylase (GAD) Autoantibody-Positive Diabetes: A Nationwide Survey in Japan. |
title_full_unstemmed |
Clinical and Genetic Characteristics of Non-Insulin-Requiring Glutamic Acid Decarboxylase (GAD) Autoantibody-Positive Diabetes: A Nationwide Survey in Japan. |
title_sort |
clinical and genetic characteristics of non-insulin-requiring glutamic acid decarboxylase (gad) autoantibody-positive diabetes: a nationwide survey in japan. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2016-01-01 |
description |
AIMS:Glutamic acid decarboxylase autoantibodies (GADAb) differentiate slowly progressive insulin-dependent (type 1) diabetes mellitus (SPIDDM) from phenotypic type 2 diabetes, but many GADAb-positive patients with diabetes do not progress to insulin-requiring diabetes. To characterize GADAb-positive patients with adult-onset diabetes who do not require insulin therapy for >5 years (NIR-SPIDDM), we conducted a nationwide cross-sectional survey in Japan. METHODS:We collected 82 GADAb-positive patients who did not require insulin therapy for >5 years (NIR-SPIDDM) and compared them with 63 patients with insulin-requiring SPIDDM (IR-SPIDDM). Clinical and biochemical characteristics, HLA-DRB1-DQB1 haplotypes, and predictive markers for progression to insulin therapy were investigated. RESULTS:Compared with the IR-SPIDDM group, the NIR-SPIDDM patients showed later diabetes onset, higher body mass index, longer duration before diagnosis, and less frequent hyperglycemic symptoms at onset. In addition, C-peptide, LDL-cholesterol, and TG were significantly higher in the NIR-SPIDDM compared to IR-SPIDDM patients. The NIR-SPIDDM group had lower frequency of susceptible HLA-DRB1*04:05-DQB1*04:01 and a higher frequency of resistant HLA-DRB1*15:01-DQB1*06:02 haplotype compared to IR-SPIDDM. A multivariable analysis showed that age at diabetes onset (OR = 0.82), duration before diagnosis of GADAb-positive diabetes (OR = 0.82), higher GADAb level (≥10.0 U/ml) (OR = 20.41), and fasting C-peptide at diagnosis (OR = 0.07) were independent predictive markers for progression to insulin-requiring diabetes. An ROC curve analysis showed that the optimal cut-off points for discriminating two groups was the GADAb level of 13.6 U/ml, age of diabetes onset of 47 years, duration before diagnosis of 5 years, and fasting C-peptide of 0.65 ng/ml. CONCLUSIONS:Clinical, biochemical and genetic characteristics of patients with NIR-SPIDDM are different from those of IR-SPIDDM patients. Age of diabetes onset, duration before GADAb-positivity, GADAb level, and fasting C-peptide at diagnosis must be carefully considered in planning prevention trials for SPIDDM. |
url |
http://europepmc.org/articles/PMC4866691?pdf=render |
work_keys_str_mv |
AT junichiyasui clinicalandgeneticcharacteristicsofnoninsulinrequiringglutamicaciddecarboxylasegadautoantibodypositivediabetesanationwidesurveyinjapan AT eijikawasaki clinicalandgeneticcharacteristicsofnoninsulinrequiringglutamicaciddecarboxylasegadautoantibodypositivediabetesanationwidesurveyinjapan AT shoichirotanaka clinicalandgeneticcharacteristicsofnoninsulinrequiringglutamicaciddecarboxylasegadautoantibodypositivediabetesanationwidesurveyinjapan AT takuyaawata clinicalandgeneticcharacteristicsofnoninsulinrequiringglutamicaciddecarboxylasegadautoantibodypositivediabetesanationwidesurveyinjapan AT hiroshiikegami clinicalandgeneticcharacteristicsofnoninsulinrequiringglutamicaciddecarboxylasegadautoantibodypositivediabetesanationwidesurveyinjapan AT akihisaimagawa clinicalandgeneticcharacteristicsofnoninsulinrequiringglutamicaciddecarboxylasegadautoantibodypositivediabetesanationwidesurveyinjapan AT yasukouchigata clinicalandgeneticcharacteristicsofnoninsulinrequiringglutamicaciddecarboxylasegadautoantibodypositivediabetesanationwidesurveyinjapan AT haruhikoosawa clinicalandgeneticcharacteristicsofnoninsulinrequiringglutamicaciddecarboxylasegadautoantibodypositivediabetesanationwidesurveyinjapan AT hiroshikajio clinicalandgeneticcharacteristicsofnoninsulinrequiringglutamicaciddecarboxylasegadautoantibodypositivediabetesanationwidesurveyinjapan AT yumikokawabata clinicalandgeneticcharacteristicsofnoninsulinrequiringglutamicaciddecarboxylasegadautoantibodypositivediabetesanationwidesurveyinjapan AT akirashimada clinicalandgeneticcharacteristicsofnoninsulinrequiringglutamicaciddecarboxylasegadautoantibodypositivediabetesanationwidesurveyinjapan AT kazumatakahashi clinicalandgeneticcharacteristicsofnoninsulinrequiringglutamicaciddecarboxylasegadautoantibodypositivediabetesanationwidesurveyinjapan AT kazukiyasuda clinicalandgeneticcharacteristicsofnoninsulinrequiringglutamicaciddecarboxylasegadautoantibodypositivediabetesanationwidesurveyinjapan AT hisafumiyasuda clinicalandgeneticcharacteristicsofnoninsulinrequiringglutamicaciddecarboxylasegadautoantibodypositivediabetesanationwidesurveyinjapan AT toshiakihanafusa clinicalandgeneticcharacteristicsofnoninsulinrequiringglutamicaciddecarboxylasegadautoantibodypositivediabetesanationwidesurveyinjapan AT tetsurokobayashi clinicalandgeneticcharacteristicsofnoninsulinrequiringglutamicaciddecarboxylasegadautoantibodypositivediabetesanationwidesurveyinjapan AT japandiabetessocietycommitteeontype1diabetesmellitusresearch clinicalandgeneticcharacteristicsofnoninsulinrequiringglutamicaciddecarboxylasegadautoantibodypositivediabetesanationwidesurveyinjapan |
_version_ |
1716803444817264640 |